ST三五(300051.SZ)擬定增募資不超3.39億元 由海南巨星科技認購
格隆匯9月28日丨ST三五(300051.SZ)披露2021年度向特定對象發行股票預案,擬向特定對象發行股票數量不超過109,709,607股(含本數),不超過發行前公司總股本的30%,並以中國證監會關於本次發行的同意註冊文件為準,全部由海南巨星科技有限公司以現金認購。
此次股票發行的特定對象為海南巨星科技有限公司;發行價為3.09元/股;募集資金總額不超過339,002,685.63元(含本數),公司在扣除發行費用後將全部用於償還有息借款和補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.